SPRY — ARS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $429.61m
- $382.44m
- $84.28m
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle
Brief: ARS Pharmaceuticals Provides Commercial And Financial Updates
U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark
U.S. STOCKS ON THE MOVE-Exxon Mobil, Intel, Nvidia
U.S. STOCKS ON THE MOVE-Shutterstock, RXO, Microsoft
U.S. STOCKS ON THE MOVE-Cerebras, Papa John's, airline stocks
ARS Pharmaceuticals rises after Q1 revenue beats estimates
ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth
Brief: ARS Pharmaceuticals Strengthens Leadership Team With Appointment Of Industry Veteran Donn Casale As President
U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems
U.S. STOCKS ON THE MOVE-Nike, PNC Financial, Papa John's
U.S. STOCKS ON THE MOVE-Gitlab, Snap, Robinhood
U.S. STOCKS ON THE MOVE-Broadcom, BofA, Snap
ARS Pharma rises after Canada clears needle-free allergy spray
Brief: Ars Pharmaceuticals Receives FDA Approval To Remove Age Requirement From Neffy® 1 Mg (Epinephrine Nasal Spray) Label
Brief: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results